Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

First Posted Date
2023-03-30
Last Posted Date
2023-07-24
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT05791097

Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Phase 2
Active, not recruiting
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: Paclitaxel
Drug: Bevacizumab
Drug: Atezolizumab
First Posted Date
2023-03-23
Last Posted Date
2024-10-11
Lead Sponsor
Intergroupe Francophone de Cancerologie Thoracique
Target Recruit Count
156
Registration Number
NCT05781308
Locations
🇫🇷

CHU Amiens, Amiens, France

🇫🇷

CHU Besançon - Hôpital J. MINJOZ, Besançon, France

🇫🇷

Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France

and more 41 locations

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

First Posted Date
2023-03-20
Last Posted Date
2024-11-20
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
180
Registration Number
NCT05775289
Locations
🇲🇽

ONCARE Viaducto Napoles, Ciudad de México, Mexico CITY (federal District), Mexico

🇪🇸

Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain

🇦🇺

Monash Health, Clayton, Victoria, Australia

and more 50 locations

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)

First Posted Date
2023-03-02
Last Posted Date
2024-10-26
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
98
Registration Number
NCT05751668
Locations
🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

🇺🇸

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

🇺🇸

Morton Plant Hospital, Clearwater, Florida, United States

and more 25 locations

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy

Phase 2
Active, not recruiting
Conditions
Breast Carcinoma
Interventions
Biological: eftilagimod alpha
Drug: Paclitaxel
Other: placebo
First Posted Date
2023-02-28
Last Posted Date
2024-12-17
Lead Sponsor
Immutep S.A.S.
Target Recruit Count
849
Registration Number
NCT05747794
Locations
🇺🇸

The Oncology Institute, Whittier, California, United States

🇺🇸

The George Washington University Cancer Center, Washington, D.C., District of Columbia, United States

🇺🇸

Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina, United States

and more 19 locations

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2023-02-23
Last Posted Date
2023-02-24
Lead Sponsor
Shandong New Time Pharmaceutical Co., LTD
Target Recruit Count
84
Registration Number
NCT05741021
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

First Posted Date
2023-02-22
Last Posted Date
2024-11-26
Lead Sponsor
Imunon
Target Recruit Count
50
Registration Number
NCT05739981
Locations
🇺🇸

Johns Hopkins Medicine SKCCC, Baltimore, Maryland, United States

🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics

First Posted Date
2023-02-16
Last Posted Date
2023-02-16
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
200
Registration Number
NCT05730777
Locations
🇨🇳

Peking University Third Hospital, Beijing, China

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 3
Recruiting
Conditions
Metastatic Hypopharyngeal Squamous Cell Carcinoma
Metastatic Laryngeal Squamous Cell Carcinoma
Stage IV Laryngeal Cancer AJCC v8
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Stage IV Hypopharyngeal Carcinoma AJCC v8
Stage IV Lip and Oral Cavity Cancer AJCC v8
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Oral Cavity Squamous Cell Carcinoma
Metastatic Oropharyngeal Squamous Cell Carcinoma
Interventions
Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Fluorouracil
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
First Posted Date
2023-02-10
Last Posted Date
2024-11-28
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
290
Registration Number
NCT05721755
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Carle Physician Group-Effingham, Effingham, Illinois, United States

🇺🇸

Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States

and more 48 locations

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

First Posted Date
2023-02-10
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
377
Registration Number
NCT05722015
Locations
🇭🇺

Törökbálinti Tüdőgyógyintézet ( Site 2105), Törökbálint, Pest, Hungary

🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 4207), Kaohsiung, Taiwan

🇺🇸

St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023), Phoenix, Arizona, United States

and more 107 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy